POPRACH, Alexandr, Zbyněk BORTLÍČEK, Tomáš BÜCHLER, Bohuslav MELICHAR, Radek LAKOMÝ, Rostislav VYZULA, Petr BRABEC, Marek SVOBODA, Ladislav DUŠEK a Jakub GREGOR. Patients with advanced and metastatic renal cell carcinoma treated with targeted therapy in the Czech Republic: twenty cancer centres, six agents, one database. Medical Oncology. roč. 29, č. 5, s. 3314-3320. ISSN 1357-0560. doi:10.1007/s12032-012-0286-9. 2012.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název Patients with advanced and metastatic renal cell carcinoma treated with targeted therapy in the Czech Republic: twenty cancer centres, six agents, one database
Autoři POPRACH, Alexandr (203 Česká republika), Zbyněk BORTLÍČEK (203 Česká republika, domácí), Tomáš BÜCHLER (703 Slovensko), Bohuslav MELICHAR (203 Česká republika), Radek LAKOMÝ (203 Česká republika), Rostislav VYZULA (203 Česká republika, garant), Petr BRABEC (203 Česká republika, domácí), Marek SVOBODA (203 Česká republika), Ladislav DUŠEK (203 Česká republika, domácí) a Jakub GREGOR (203 Česká republika, domácí).
Vydání Medical Oncology, 2012, 1357-0560.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 30200 3.2 Clinical medicine
Stát vydavatele Česká republika
Utajení není předmětem státního či obchodního tajemství
Impakt faktor Impact factor: 2.147
Kód RIV RIV/00216224:14110/12:00062394
Organizační jednotka Lékařská fakulta
Doi http://dx.doi.org/10.1007/s12032-012-0286-9
UT WoS 000311513800045
Klíčová slova anglicky kidney cancer; renal carcinoma; epidemiology; incidence
Změnil Změnila: Ing. Mgr. Věra Pospíšilíková, učo 9005. Změněno: 23. 4. 2013 00:18.
Anotace
The incidence and mortality of renal cell carcinoma (RCC) in the Czech Republic are among the highest in the world. Several targeted agents have been recently approved for the treatment of advanced/metastatic RCC. Objective: Presentation of a national clinical database for monitoring and assessment of patients with advanced/metastatic RCC treated with targeted therapy. The RenIS (RENal Information System, http://renis.registry.cz) registry is a noninterventional post-registration database of epidemiological and clinical data of patients with RCC treated with targeted therapies in the Czech Republic. Twenty cancer centres eligible for targeted therapy administration participate in the project. As of November 2011, six agents were approved and reimbursed from public health insurance, including bevacizumab, everolimus, pazopanib, sorafenib, sunitinib, and temsirolimus. As of 10 October 2011, 1,541 patients with valid recordswere entered into the database.Comparison with population-based data from the Czech National Cancer Registry revealed that RCC patients treated with targeted therapy are significantly younger (median age at diagnosis 59 vs. 66 years). Most RenIS registry patients were treated with sorafenib and sunitinib, many patients sequentially with both agents. Over 10 % of patients were also treated with everolimus in the second or third line. Progression-free survival times achieved were comparable to phase III clinical trials. The RenIS registry has become an important tool and source of information for the management of cancer care and clinical practice, providing comprehensive data onmonitoring and assessment of RCC targeted therapy on a national level.
VytisknoutZobrazeno: 28. 3. 2024 16:58